Tamarack Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Tamarack Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,000	Closed	-$2.8M	–	60
2021 Q4	$2.8M	Buy	+25,000	New	+$3.02M	1.15%	34

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Tamarack Advisers's XBI Position: Q1 2022 in Review

Tamarack Advisers sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 25,000 shares — an estimated $2.8M sold.

Tamarack Advisers first reported a position in XBI in Q4 2021 and held it in 1 quarter. The position peaked at $2.8M in Q4 2021. 702 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

Tamarack Advisers reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
Tamarack Advisers sold 25,000 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $2.8M.
Tamarack Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 1 quarter.
Tamarack Advisers's State Street SPDR S&P Biotech ETF position peaked at $2.8M in Q4 2021.
702 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Tamarack Advisers's 13F filing for Q1 2022, filed 11 May 2022.